Vigintillion Capital is a professional private equity firm approved by the Asset Management Association of
China (AMAC)（Registration No. P1061033)，We are founded by industry veterans and supported by several well
respected financial and industrial conglomerates.
Vigintillion Capital focuses on private equity investment in life sciences and healthcare. We mainly invest
in promising growth and maturity stage companies in China and abroad. While creating value for investors, we
adhere to the principle that financial investment should be performed with industrial aspiration in mind. In
all of our proposed or invested projects, we have proposed or transmitted tailor-made strategic values to
target companies to support their long-term development.
Vigintillion Capital has built hundreds of industry research ecosystems, which covering about 20 medical and
health sub-sectors, under our strong ability of active analysis and independent exploration. Our existing
portfolio covers biotech, small molecule FIC/BIC, CDMO, structural cardiovascular device, SaaS etc..
In April 2016, China Resources Medical injected its main medical assets into Phoenix Healthcare Group (1515.HK), a listed company in Hong Kong. After the reorganization, Phoenix Healthcare was renamed China Resources Phoenix Healthcare Group, and China Resources Medical became the largest shareholder. The reorganized China Resources Phoenix Healthcare operates 107 hospitals with 11,780 beds in mainland China, making it the largest medical service group in Asia. In the same year, under the leadership of China Resources Medical, China Resources Phoenix Healthcare invested in Vigintillion Capital and both parties signed a Comprehensive Strategic Cooperation Agreement.
China Cinda Asset Management Co., Ltd. is a state-owned non-banking financial institution approved by the State Council and owned by the Ministry of Finance. On December 12th, 2013, China Cinda was listed on the main board of the Stock Exchange of Hong Kong. By the end of 2017, China Cinda's total asset amounted to 1386.9 billion RMB. In the 2007 issue of Fortune China 500, Cinda ranked 78th in operating revenue and 31st in profit.
Yuexiu Group was established in Hong Kong in 1985. After 35 years of reform and development, the Group has formed a “4+X” modern industrial system with core industries such as finance, real estate, transportation infrastructure, agriculture and food and emerging industries such as healthcare and high-tech. By the end of 2019, the total assets reached RMB666.2bn, among which the total assets of the financial sector exceeded RMB310bn. The company owns two financial holding platform listed companies, Guangzhou Yuexiu Financial Holding (000987.SZ) and Hong Kong Yuexiu Financial Holding (01111.HK). Guangzhou Yuexiu Financial Holdings Group was established in 2012, which was a crucial strategic progress of Yuexiu Group’s financial core industry layout. In 2016, the company entered the capital market, and became the first local financial holdings listed platform in China. The company currently has financial business platforms such as Guangzhou Assets, Yuexiu Leasing, Yuexiu Industrial Fund, Yuexiu Financial Holding Capital, Yuexiu Guarantee, Guangzhou Futures, Yuexiu Fintech, etc., and is the second largest shareholder of Citic Securities. After 8 years of development, the total assets of the company has been nearly RMB120bn.
China Pharmaceutical University (CPU) is known for its long history and its leading role in China’s pharmaceutical academia. It is one of the “211 project” key universities affiliated to the Ministry of Education of China, and listed among the “Double First-Class” universities in China. The University was founded in 1936 as China’s first independent four-year National College of Pharmacy and the first public institution for higher pharmaceutical education in China. Over the 80 years, it has been making important contributions to promote the development of national healthcare, which well represents its motto “Dedicated to academic excellence and devoted to public health.” The School of Basic Medical Sciences and Clinical Pharmacy focuses on the investigations of pathogenesis of major diseases, the efficacy and mechanisms of innovative drugs, rational use of clinical medicines and post-marketing re-evaluation, by integrating the advantages of both basic medical sciences and clinical pharmacy, along with the support of clinical institutions. It will also strengthen solve-scientific problems such as the cause of major diseases, rational use of drugs and precise medicine, in order to improve its abilities of scientific innovations and services.
Kevin Guan
Chairman and Founding Partner
Mr. Kevin Guan has over 20 years of experience in capital market investment in China, U.S., Southeast Asia, and the Middle East. Prior to founding Vigintillion, Mr. Guan has served as Executive Director and person in charge of healthcare investment at Pacific Alliance Group (PAG) with an AUM of 30 billion USD. At Vigintillion, he is responsible for investment strategy,risk management, project development and overall operations of the fund. Mr. Guan holds an M.B.A. from Wharton Business School and an E.M.B.A. from PBC School of Finance at Tsinghua University. Chartered Financial Analyst (CFA), Certified Public Accountant (CPA), Vice Chairman of ASEAN Economic Cooperation Foundation China Affairs Department, Director of Tsinghua PBC Intelligent Finance Center, Member of China Youth Entrepreneurs Association.
Brook Wu
Managing Director and Partner
Mr. Brook Wu has nearly 30 years of experience in the field of pharmaceutical and healthcare. He has
served as a senior executive in Pfizer, MSD, Abbott, Takeda, Mundipharma, China Resources Double-Crane
and other multinational or domestic enterprises.He has objective and profound knowledge, as well as
unique views on the pharmaceutical industry. At Vigintillion, Mr. Wu is responsible for investment
strategy, project development, investment execution and post-investment management. Mr. Wu holds a
Bachelor of Pharmacy from China Pharmaceutical University and an M.B.A. from Marshall Business School
at University of Southern California.and is the founder of China Pharmaceutical BD Alliance.
At Vigintillion, he is responsible for investment strategy, project development, investment execution
and post-investment management.
